Products

J.D.KRUEGER & COMPANY

Uses AI

Mehr Umsatz aus Ihrem Shop. Oder Sie zahlen nichts.

jdk.de Marketing / Conversion Optimization & Social Proof

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Usage-based
No monthly subscription pricing
Creators
Jörg Dennis Krüger
@jdk· 1,343 followers
Launched
4y ago
2022-07-01 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
X accounts@jdk
  • Launched on Product HuntLaunch

    Digital coaching, training, and consulting

    Jul 1, 2022 · 4y agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Direct31%
  • Organic Search29%
  • Referrals10%
  • Social7%
  • Other23%

Countries

  • Germany100%

Search

Domain authority —Domain registered Unknown

KeywordMonthly volume
upselling8,780
ab test3,110
ho3 5 millionen130
wie viele besucher für ecom a/b test pro variante100
jd krüger30

Traffic data: Vaneform

Pricing

Usage-based pricing; no fixed plans listed on website.

Trial: Der 14-Tage-Pilot ist komplett kostenlos und unverbindlich. · Observed 2026-11-05 · Pricing page

Pages & changes

Tracked since 2022-07-01

Key pages

Weekly snapshots
jdk.de/ Snapshot 2026-11-04

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does J.D.KRUEGER & COMPANY get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is J.D.KRUEGER & COMPANY and what platforms does it support?
J.D.KRUEGER & COMPANY is catalogued under Conversion Optimization & Social Proof: Mehr Umsatz aus Ihrem Shop. Oder Sie zahlen nichts. Supported platforms: Web.

Related products in this category

Marketing / Conversion Optimization & Social Proof

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.